Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
enGene TherapeuticsFRA:S0N0 -2.05%19 Quick Ratio is 12.57 as of Apr. 2026, which is at its 10-year median of 12.57. GuruFocus rates FRA:S0N0 with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 1,405 Biotechnology companies, enGene Therapeutics ranks better than 83.42% on this metric.
enGene Therapeutics (FRA:S0N0) Quick Ratio Explanation
The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.
In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.
The higher the quick ratio, the better the company's liquidity position.
enGene Therapeutics Quick Ratio Related Terms
enGene Therapeutics Quick Ratio Historical Data
* Premium members only.
The historical data trend for enGene Therapeutics's Quick Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:S0N0 vs VTVT, GUTS, VXRT: Quick Ratio Comparison
For the Biotechnology subindustry, enGene Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
enGene Therapeutics Quick Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, enGene Therapeutics's Quick Ratio distribution charts can be found below:
* The bar in red indicates where enGene Therapeutics's Quick Ratio falls into.
The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.
enGene Therapeutics's Quick Ratio for the fiscal year that ended in Oct. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
enGene Therapeutics (FRA:S0N0) has a Quick Ratio of 12.57 as of Apr. 2026. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on enGene Therapeutics and its competitors. This is near median its historical median of 12.57. Over the past decade, enGene Therapeutics' Quick Ratio has ranged from 1.25 to 42.80. According to the industry distribution chart, enGene Therapeutics ranks #233 out of 1405 companies in the Biotechnology industry, placing it in the top 16.6%.
Is enGene Therapeutics' Quick Ratio too high?
enGene Therapeutics' current Quick Ratio of 12.57 is near median its 10-year median of 12.57. Over the past 10 years, this metric has ranged from a low of 1.25 to a high of 42.80. The Biotechnology industry median Quick Ratio is 3.57. enGene Therapeutics' value of 12.57 is 252.1% above this industry median. Based on the distribution chart, enGene Therapeutics ranks #233 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, enGene Therapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does enGene Therapeutics' Quick Ratio compare to VTVT and GUTS?
According to the Biotechnology industry distribution chart, enGene Therapeutics ranks #233 out of 1405 companies for Quick Ratio. This places enGene Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Quick Ratio is 3.57. enGene Therapeutics' value of 12.57 is 252.1% above this benchmark. Historically, enGene Therapeutics' own Quick Ratio has ranged from 1.25 to 42.80 over the past decade. While the company's 10-year median is 12.57 vs. the industry median of 3.57, enGene Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Quick Ratio for a Biotechnology company?
The median Quick Ratio among Biotechnology companies is 3.57, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Quick Ratio significantly above this median, while those in the bottom quartile fall well below. However, Quick Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. enGene Therapeutics's current Quick Ratio of 12.57 is 252.1% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Quick Ratio mean?
A high Quick Ratio can signal that a stock is expensive relative to its fundamentals. Quick ratio is the ratio of current assets less inventory to current liabilities. View historical data on enGene Therapeutics and its competitors. For the Biotechnology industry, the median Quick Ratio is 3.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. enGene Therapeutics's current Quick Ratio is 12.57, which is near median its own 10-year median of 12.57. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is enGene Therapeutics stock overvalued right now?
enGene Therapeutics (FRA:S0N0) has a current Quick Ratio of 12.57. The current Quick Ratio is 12.57, which is near median its 10-year median of 12.57 and 252.1% above the Biotechnology industry median of 3.57. enGene Therapeutics' overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Quick Ratio calculated?
Quick Ratio is calculated from a company's financial statements. For enGene Therapeutics (FRA:S0N0), the current Quick Ratio is 12.57 as of Apr. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
enGene Therapeutics Inc is a clinical-stage biotechnology company mainstreaming gene therapy through the delivery of therapeutics to mucosal tissues and other organs, to create new ways to address diseases with high clinical needs. Its pioneering program is detalimogene voraplasmid (also known as detalimogene) for patients with Non-Muscle Invasive Bladder Cancer (NMIBC), a disease with a high clinical burden. Detalimogene is being evaluated in the ongoing multi-cohort LEGEND Phase 2 trial, which includes a pivotal cohort studying detalimogene in high-risk, Bacillus Calmette-Guerin (BCG)-unresponsive patients with carcinoma in situ (CIS) with or without concomitant papillary disease. It is developed using enGene's proprietary Dually Derivatized Oligochitosan (DDX) platform.
19GF Score
Get the complete analysis for FRA:S0N0
Quick Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:S0N0 has been successfully added to your 
